MRG007
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced or Metastatic Solid Tumors
Conditions
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Trial Timeline
Jul 25, 2025 → Dec 1, 2030
NCT ID
NCT07066657About MRG007
MRG007 is a phase 1 stage product being developed by ArriVent Biopharma for Locally Advanced or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07066657. Target conditions include Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced or Metastatic Solid Tumors were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
6
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07066657 | Phase 1 | Recruiting |
Competing Products
20 competing products in Locally Advanced or Metastatic Solid Tumors